BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

Stimulants are the most effective drugs for ADHD, but the very things that make them effective - blocking norepinephrine and dopamine reuptake - can also lead to addiction and cause anxiety. Neurovance Inc .'s lead candidate for...
BC Week In Review | Jun 3, 2013
Clinical News

Amitifadine: Phase IIb/IIIa data

Top-line data from the double-blind, U.S. Phase IIb/IIIa TRIADE trial in 342 patients with MDD showed that once-daily 50 and 100 mg doses of amitifadine each missed the primary endpoint of improving MADRS score from...
BC Week In Review | Oct 22, 2012
Clinical News

Amitifadine: Completed Phase IIb/IIIa enrollment

Euthymics completed enrollment of 342 patients in the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial comparing 50 and 100 mg amitifadine vs. Paxil paroxetine for 12 weeks in patients with an inadequate response to a...
BioCentury | Oct 22, 2012
Finance

Maximizing depression

Maximizing depression Euthymics Bioscience Inc. thinks spinning out its early stage assets into Neurovance Inc. will make it easier to partner Euthymics' lone remaining asset - its amitifadine candidate for depression. The two companies will have...
BC Extra | Oct 19, 2012
Company News

Euthymics' Neurovance spinout raises $7M

Neurovance Inc. (Cambridge, Mass.) emerged Thursday as a spinout of Euthymics Bioscience Inc. (Cambridge, Mass.) with $7 million raised in a series A round. Existing Euthymics investors financed the Neurovance round, including lead investor Novartis...
BioCentury | Dec 5, 2011
Emerging Company Profile

Euthymics: Balancing act

Euthymics Bioscience Inc. thinks a molecule orphaned by Dov Pharmaceutical Inc. has the right relative ratio of monoamine reuptake inhibition to offer better efficacy and tolerability than marketed antidepressants. About 60% of MDD patients fail...
BC Week In Review | Mar 21, 2011
Clinical News

EB-1010: Phase IIb/IIIa started

Euthymics began the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial to compare 50 and 100 mg EB-1010 vs. Paxil paroxetine for 12 weeks in about 300 patients. Euthymics gained the compound through its reverse-merger with...
BC Week In Review | Dec 13, 2010
Clinical News

EB-1010: Phase II data

Data from the modified intent-to-treat (mITT) population (n=56) of a double-blind, U.S. and European Phase II trial showed that EB-1010 met the primary endpoint of significantly improving MADRS total score at week 6 vs. placebo...
BC Extra | Dec 9, 2010
Clinical News

Euthymics' EB-1010 meets depression endpoint

Euthymics Bioscience Inc. (Cambridge, Mass.) said EB-1010 met the primary endpoint vs. placebo in a Phase II trial to treat major depressive disorder (MDD). In the modified intent-to-treat population of 56 patients, EB-1010 significantly improved...
BioCentury | Jul 26, 2010
Finance

Bear out of Hibernation

Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc. , which VCs financed with $24 million in a tranched series...
Items per page:
1 - 10 of 29